NCT00828438已完成1 期
A Phase 1, Open-Label, Single-Dose Study of the Pharmacokinetic Properties of Lorcaserin in Subjects With Renal Impairment
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Eisai Inc.
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- The primary objective of this study is to assess the pharmacokinetic properties of lorcaserin in subjects with mild, moderate or severe renal impairment as compared to subjects with normal renal function.
研究概览
简要总结
The purpose of this study is to evaluate the PK properties of lorcaserin in subjects with end stage renal disease (ESRD) who require dialysis and will be studied under dialysis and non-dialysis conditions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 79 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Males or females aged between 18 and 79 years (inclusive)
- •Able to give signed informed consent
- •Renal function will fall into one of the following categories (ideal body weight will be used for the calculation):
- •One-fifth of subjects will have normal renal function, defined as creatinine clearance > 80 mL/min calculated using the Cockroft-Gault equation
- •One-fifth of subjects will have creatinine clearance 51-80 mL/min
- •One-fifth of subjects will have creatinine clearance 31-50 mL/min
- •One-fifth of subjects will have creatinine clearance 5-30 mL/min, but not require dialysis
- •One-fifth of subjects will have chronic end stage renal disease, require regularly scheduled hemodialysis, and be on a stable hemodialysis regimen for at least 3 months prior to dosing
- •Subjects in the renally impaired groups will have stable renal disease as per Investigator's assessment, with no clinically meaningful changes for 1 month prior to randomization.
- •Subjects in all groups will have a BMI of 27-45 kg/m
- •Considered to be in stable health in the opinion of the Investigator.
- •Eligible male and female subjects must agree not to participate in a conception process.
排除标准
- •Prior participation in any study of lorcaserin.
- •Clinically significant new illness in the 1 month before screening
- •Not suitable to participate in the study in the opinion of the Investigator including an existing physical or mental condition that prevents compliance with the protocol
- •History of any of the following cardiovascular conditions:
- •Myocardial infarction (diagnosed by cardiac enzyme[s] and/or diagnostic ECG), CVA, TIA or RIND within 3 months of screening
- •Cardiac arrhythmia requiring initiation of a new medical or surgical treatment within 3 months of screening (pacemaker and/or defibrillator implanted > 3 months prior to screening is acceptable)
- •Unstable angina
- •History of pulmonary artery hypertension
- •Positive result of HIV, hepatitis B or hepatitis C screens.
- •Malignancy within 2 years of the screening visit (except basal cell or squamous cell carcinoma with clean surgical margins)
- •Use of SSRI's, SNRI's, and other medications must meet washout period.
- •Recent history (within 3 months prior to the screening visit) of alcohol or drug/solvent abuse or a positive screen for drugs of abuse at screening.
- •Participated in any clinical study with an investigational drug, biologic, or device within 1 month prior to dosing
- •Unwilling, or whose partner is unwilling, to use an adequate means of contraception during and for 1 month following completion/withdrawal of the study
研究组 & 干预措施
Lorcaserin 10mg
Experimental
干预措施: Lorcaserin 10mg (Drug)
结局指标
主要结局
The primary objective of this study is to assess the pharmacokinetic properties of lorcaserin in subjects with mild, moderate or severe renal impairment as compared to subjects with normal renal function.
次要结局
- To evaluate the safety and tolerability of lorcaserin in subjects with renal impairment.
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Single Dose Study to Determine the Safety, Tolerability, and Pharmacokinetic Properties of Lorcaserin Hydrochloride (BELVIQ) in Obese Adolescents From 12 to 17 Years of AgePharmacokinetics in Obese AdolescentsNCT02022956Eisai Inc.8
已完成
1 期
Pharmacokinetic Properties of Lorcaserin in Obese or Overweight Elderly SubjectsObesityNCT00828581Eisai Inc.24
已完成
1 期
Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic ImpairmentHepatic ImpairmentNCT00828932Eisai Inc.24
Unknown
1 期
Study to Evaluate the Pharmacokinetic Characteristics of Pegylated Exenatide Injection (PB-119) in Subjects With Different Degrees of Renal Insufficiency and Matched Subjects With Normal Renal FunctionType2DiabetesNCT05328843PegBio Co., Ltd.24
已完成
1 期
A Study of Subcutaneous KY1005 in Healthy VolunteersImmune System DiseasesNCT04449939Kymab Limited24